2-Chlorodeoxyadenosine: An Effective New Agent for the Treatment of Chronic Lymphocytic Leukemia

2-Chlorodeoxyadenosine, a new lymphocyte-selective, anti-neoplastic drug was administered to 18 patients with advanced chronic lymphocytic leukemia of B-cell origin. All patients were resistant to conventional treatment. A total of 44 courses of 2-chlorodeoxyadenosine were completed with minimal tox...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1988-09, Vol.72 (3), p.1069-1073
Main Authors: Piro, Lawrence D., Carrera, Carlos J., Beutler, Ernest, Carson, Dennis A.
Format: Article
Language:English
Subjects:
Adult
Aged
Anemia, Hemolytic, Autoimmune - blood
Anemia, Hemolytic, Autoimmune - drug therapy
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - blood
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chemotherapy
Cladribine
Deoxyadenosines - adverse effects
Deoxyadenosines - analogs & derivatives
Deoxyadenosines - blood
Deoxyadenosines - therapeutic use
Female
Humans
Leukemia, Lymphoid - drug therapy
Leukemia, Lymphoid - pathology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Remission Induction
Tumor Cells, Cultured - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:2-Chlorodeoxyadenosine, a new lymphocyte-selective, anti-neoplastic drug was administered to 18 patients with advanced chronic lymphocytic leukemia of B-cell origin. All patients were resistant to conventional treatment. A total of 44 courses of 2-chlorodeoxyadenosine were completed with minimal toxicity. An overall response rate of 55% was achieved with four of 18 patients demonstrating partial response and six of 18 patients experiencing clinical improvement. Only minor bone marrow suppression occurred during administration of the drug, indicating a high degree of lymphocyte selectivity. Reduction of lym- phocyte infiltration in bone marrow occurred in treated patients including one patient who experienced normalization of the bone marrow. Three of four patients with concurrent autoimmune hemolytic anemia experienced resolution of hemolysis, as indicated by elimination of transfusion requirement, fall in reticulocyte count, elevation of hemoglobin, and ability to taper prednisone without recurrence of hemolysis. Duration of responses ranged from 2 to 15 months without maintenance therapy. © 1988 by Grune & Stratton, Inc.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V72.3.1069.1069